Top-News

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
24,50 €
+0,1 €
+0,41%
14:47:10 Uhr
Depot/Watchlist
Marktkapitalisierung *
25,14 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,29%
Faktor
1
Originalaktie
IL0006290147
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,11: VH0A9A
Werbung

Teva Pharmaceutical Aktie (ADR) News

04.12.25 - dpa-AFX
KORREKTUR/Pharmabranche: Engpässe bei Kinderarzneien sind gesunken
Bisherige Schritte der Politik gegen Arznei-​Engpässe in Deutschland haben aus Sicht des Pharmaverbands Pro Generika nur begrenzt geholfen. Zwar habe sich die Versorgung bei ...
04.12.25 - dpa-AFX
Pharmabranche: Keine Entspannung bei Engpässen von Kinderarzneien
Bisherige Schritte der Politik gegen Arznei-​Engpässe in Deutschland haben aus Sicht des Pharmaverbands Pro Generika nur begrenzt geholfen. Zwar habe sich die Versorgung bei ...
26.11.25 - GlobeNewswire
Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®
Aufgrund der positiven Stellungnahmen des Ausschusses für Humanarzneimittel (CHMP) hat die Europäische Kommission die Zulassungen für die Biosimilars PONLIMSI und ...
25.11.25 - GlobeNewswire
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP ) , the European Commission has granted marketing authorizations for Teva’s ...
21.11.25 - GlobeNewswire
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
19.11.25 - GlobeNewswire
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
First cohort features 7 real-​world challenges across R&D, manufacturing and supply chain, commercial and medical affairs  Teva's first-​ever global innovation platform aims to ...
08.11.25 - GlobeNewswire
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking ...
05.11.25 - GlobeNewswire
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com
03.11.25 - GlobeNewswire
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
This football season, Teva is increasing education around tardive dyskinesia (TD) by  launching ‘The Other TD’ campaign TD is a chronic movement disorder impacting one in four ...
31.10.25 - GlobeNewswire
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
21.10.25 - GlobeNewswire
Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa
Teva und Prestige geben eine Lizenz- und Liefervereinbarung für die Vermarktung des von Prestige hergestellten Arzneimittels Tuznue ® bekannt, einem Biosimilar zu Herceptin ® ...
20.10.25 - GlobeNewswire
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received ...
10.10.25 - GlobeNewswire
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY ® (risperidone) extended-​release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the ...
06.10.25 - kapitalerhoehungen.de
Kleine Innovationen, große Gewinne: Wie smarte Wirkstofftechnologien den Biotech-Markt neu aufrollen!
Foto: pixabay.com Wer in Biotech investiert, der wünscht sich, das nächste große Ding im Depot zu haben: Wirkstoffe, die alles revolutionieren, Technologien, die den Unterschied ...
25.09.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third ...
25.09.25 - GlobeNewswire
Teva Releases Q3 2025 Aide Memoire
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available ...
23.09.25 - dpa-AFX
Trump warnt Schwangere vor Paracetamol: Experte widerspricht
US-​Präsident Donald Trump hat schwangere Frauen wegen angeblicher Autismus-​Gefahr für ihre Kinder vor der Einnahme von Paracetamol gewarnt - Experten widersprechen ihm ...
21.09.25 - GlobeNewswire
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-​release ...
21.09.25 - GlobeNewswire
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-​injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) ...
16.09.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »